Sarepta hikes full-year sales estimate for Duchenne drug
July 19, 2017 at 16:11 PM EDT
The FDA approved the drug last year despite limited clinical data and in the face of intense pressure from patient groups. Some insurers are still hesitant to reimburse it.
